Michael A. Metzger, MBA
President and Chief Executive Officer
Michael A. Metzger joined Regado in December 2013 as President and Chief Operating Officer. Mr. Metzger has nearly 20 years of experience within the life sciences and pharmaceuticals industries. Mr. Metzger has a distinguished track record of building value for shareholders through product and company acquisitions as well as organic growth by leveraging pharmaceutical partnerships.
Prior to joining Regado, from April 2011 to November 2013, Mr. Metzger held the position of Executive Vice President and Chief Operating Officer at Mersana Therapeutics, a private, venture-financed, biopharmaceutical company developing next generation antibody drug conjugates for oncology. At Mersana, he established key business alliances and helped architect the strategic direction, financing and growth of the business which led to Mersana being named a Fierce15 Biotech Company in 2012. Prior to joining Mersana in early 2011, Mr. Metzger held senior positions within Business Development and led Mergers and Acquisitions at Forest Laboratories, Inc. where he completed deals with numerous specialty pharmaceutical and biotechnology companies including Cerexa, Novexel, Ironwood Pharmaceuticals and Clinical Data, Inc.
Prior to his time at Forest, Mr. Metzger was Vice President Corporate Development at Onconova Therapeutics, Inc., from 2001 until 2006. At Mesa Partners, Inc., a venture capital firm from 1997 to 2001, he was Managing Director. Mr. Metzger served as a member of the Board of Directors of Response Genetics, Inc., a company focused on the development and commercialization of molecular diagnostic tests for cancer from 2010 to November 2013. Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.
Don Elsey, MBA
Senior Vice President, Finance and Chief Financial and Compliance Officer
Don Elsey joined Regado in May 2014 as Senior Vice President, Finance and Chief Financial Officer. Prior to joining the Company, from December 2012 to February 2014 Mr. Elsey served as chief financial officer of LifeCell, Inc., a privately held regenerative medicine company. From June 2005 to December 2012, he served in numerous finance capacities, most recently as senior vice president and chief financial officer, at Emergent BioSolutions Inc., a publicly held biopharmaceutical company.
He served as the director of finance and administration at IGEN International, Inc., a publicly held biotechnology company, and its successor BioVeris Corporation, from April 2000 to June 2005. Prior to joining IGEN, Mr. Elsey served as director of finance at Applera, a genomics and sequencing company, and in several finance positions at International Business Machines, Inc. Mr. Elsey serves on the board of directors of RegeneRx Biopharmaceuticals, a publicly traded biopharmaceuticals company. He received an M.B.A. in finance and a B.A. in economics from Michigan State University. Mr. Elsey is a certified management accountant.Read less »
Chris Rusconi, Ph.D.
SVP Discovery/Preclinical Development and Chief Scientific Officer
Chris Rusconi Ph.D. is a co-founder of Regado and serves as the Company’s Chief Scientific Officer.
Prior to joining Regado in 2003, Dr. Rusconi was Director of Research for the Program in Combinatorial Therapeutics and Assistant Research Professor of Surgery at Duke University Medical Center. As Director of Research, he focused on the discovery and early development of nucleic acid-based therapeutics by integrating input from leading clinicians with the technologic know-how of basic and translational scientists.
Dr. Rusconi has authored or co-authored more than 30 peer-reviewed publications, including works appearing in Nature, Circulation and the Journal of Clinical Investigation. He is the co-inventor of the Regado technology and the Company’s lead program, the REG1 Anticoagulation System, and has led the development of this program from discovery into phase 2 testing.
Dr. Rusconi earned a Bachelor of Science degree in the Honors Program in Cellular Biology from the University of Kansas, and a Ph.D. in Molecular and Cellular Biology from the University of Colorado, Boulder. He continued his training as a Jane Coffin Childs postdoctoral fellow at Duke University Medical Center.Read less »